{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:31:51Z","timestamp":1777555911475,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2455-2","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T17:09:47Z","timestamp":1468429787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation"],"prefix":"10.1186","volume":"16","author":[{"given":"Kelong","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Claret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,13]]},"reference":[{"key":"2455_CR1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0169-5002(97)00084-6","volume":"19","author":"JP Sculier","year":"1998","unstructured":"Sculier JP, Berghmans T, Castaigne C, et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer. 1998;19:141\u201351.","journal-title":"Lung Cancer"},{"issue":"8","key":"2455_CR2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2012.43.7459","volume":"31","author":"DE Gerber","year":"2013","unstructured":"Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol. 2013;31(8):1009\u201320.","journal-title":"J Clin Oncol"},{"key":"2455_CR3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2013.152","volume":"10","author":"R Rosell","year":"2013","unstructured":"Rosell R, Karachaliou N. Maintenance therapy and precision medicine in NSCLC. Nat Rev Clin Oncol. 2013;10:549\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2455_CR4","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/annonc\/mdt529","volume":"25","author":"V Polo","year":"2014","unstructured":"Polo V, Besse B. Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? Ann Oncol. 2014;25(7):1283\u201393.","journal-title":"Ann Oncol"},{"key":"2455_CR5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/clpt.2014.4","volume":"95","author":"R Bruno","year":"2014","unstructured":"Bruno R, Mercier F, Claret L. Evaluation of tumor-size response metrics to predict survival in oncology clinical trials. Clin Pharmacol Ther. 2014;95:386\u201393.","journal-title":"Clin Pharmacol Ther"},{"key":"2455_CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.7","volume":"97","author":"K Venkatakrishnan","year":"2015","unstructured":"Venkatakrishnan K, Friberg LE, Ouellet D, Mettetal JT, Stein A, Troc\u00f3niz IF, et al. Optimizing oncology therapeutics through quantitative clinical pharmacology: challenges and opportunities. Clin Pharmacol Ther. 2015;97:37\u201354.","journal-title":"Clin Pharmacol Ther"},{"key":"2455_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2014.57.2826","volume":"33","author":"MR Sharma","year":"2015","unstructured":"Sharma MR, Gray E, Goldberg RM, et al. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. J Clin Oncol. 2015;33:36\u201341.","journal-title":"J Clin Oncol"},{"key":"2455_CR8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/clpt.2009.64","volume":"86","author":"Y Wang","year":"2009","unstructured":"Wang Y et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther. 2009;86:167\u201374.","journal-title":"Clin Pharmacol Ther"},{"key":"2455_CR9","doi-asserted-by":"crossref","first-page":"e19049","DOI":"10.1200\/jco.2013.31.15_suppl.e19049","volume":"31","author":"L Claret","year":"2013","unstructured":"Claret L, Mancini P, Sebastien B, Veyrat-Follet C, Bruno R. Model-based estimates of tumor growth inhibition metrics to predict for overall survival in first-line non-small cell lung cance. J Clin Oncol. 2013;31:e19049.","journal-title":"J Clin Oncol"},{"key":"2455_CR10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/clpt.2014.11","volume":"95","author":"L Claret","year":"2014","unstructured":"Claret L, Bruno R, Lu JF, Sun YN, Hsu CP. Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results. Clin Pharmacol Ther. 2014;95:446\u201351.","journal-title":"Clin Pharmacol Ther"},{"key":"2455_CR11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","volume":"11","author":"F Cappuzzo","year":"2010","unstructured":"Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo controlled phase 3 study. Lancet Oncol. 2010;11:521\u20139.","journal-title":"Lancet Oncol"},{"key":"2455_CR12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/annonc\/mdr125","volume":"23","author":"B Coudert","year":"2012","unstructured":"Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol. 2012;23:388\u201394.","journal-title":"Ann Oncol"},{"issue":"31","key":"2455_CR13","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1200\/JCO.2012.47.3983","volume":"31","author":"BE Johnson","year":"2013","unstructured":"Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, et al. ATLAS: Randomized, double-blind, placebo controlled, phase IIIb trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31(31):3926\u201334.","journal-title":"J Clin Oncol"},{"key":"2455_CR14","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","volume":"31","author":"F Barlesi","year":"2013","unstructured":"Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31:3004\u201311.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2455_CR15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mdu098","volume":"25","author":"F Barlesi","year":"2014","unstructured":"Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikstr\u00f6m A, Chouaid C, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014;25(5):1044\u201352.","journal-title":"Ann Oncol"},{"key":"2455_CR16","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1200\/JCO.2012.45.0973","volume":"31","author":"L Claret","year":"2013","unstructured":"Claret L, Gupta M, Han K, et al. Evaluation of tumor size response metrics to predict overall survival in western and Chinese patients with first line metastatic colorectal cancer. J Clin Oncol. 2013;31:2110\u20134.","journal-title":"J Clin Oncol"},{"key":"2455_CR17","volume-title":"NONMEM users guides","author":"SL Beal","year":"1992","unstructured":"Beal SL, Sheiner LB. NONMEM users guides. San Francisco: NONMEM Project Group, University of California at San Francisco; 1992."},{"key":"2455_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European organization for research and treatment of cancer, National cancer Institute of the United States, National cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"2455_CR19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2455_CR20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558\u201369.","journal-title":"AAPS J"},{"key":"2455_CR21","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2014","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. URL: http:\/\/www.R-project.org\/ ."},{"key":"2455_CR22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716\u201323.","journal-title":"IEEE Trans Autom Control"},{"key":"2455_CR23","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1200\/JCO.1991.9.11.2002","volume":"9","author":"RR Ellison","year":"1991","unstructured":"Ellison RR, Mick R, Cuttner J, et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by cancer and leukemia group B. J Clin Oncol. 1991;9:2002\u201315.","journal-title":"J Clin Oncol"},{"key":"2455_CR24","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(96)91615-3","volume":"347","author":"Childhood ALL Collaborative Group","year":"1996","unstructured":"Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet. 1996;347:1783\u20138.","journal-title":"Lancet"},{"key":"2455_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"key":"2455_CR26","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","volume":"103","author":"L Vidal","year":"2011","unstructured":"Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103:1799\u2013806.","journal-title":"J Natl Cancer Inst"},{"key":"2455_CR27","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770\u201381.","journal-title":"N Engl J Med"},{"key":"2455_CR28","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199111073251904","volume":"325","author":"HB Muss","year":"1991","unstructured":"Muss HB, Case LD, Richards 2nd F, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer: the piedmont oncology association. N Engl J Med. 1991;325:1342\u20138.","journal-title":"N Engl J Med"},{"key":"2455_CR29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(03)12461-0","volume":"361","author":"TS Maughan","year":"2003","unstructured":"Maughan TS, James RD, Kerr DJ, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361:457\u201364.","journal-title":"Lancet"},{"issue":"suppl 3","key":"2455_CR30","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0305-7372(10)70019-0","volume":"36","author":"F Giuliani","year":"2010","unstructured":"Giuliani F, De Vita F, Colucci G, et al. Maintenance therapy in colon cancer. Cancer Treat Rev. 2010;36 suppl 3:S42\u20135.","journal-title":"Cancer Treat Rev"},{"key":"2455_CR31","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","volume":"21","author":"M Markman","year":"2003","unstructured":"Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3\u00a0months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a southwest oncology group and gynecologic oncology group trial. J Clin Oncol. 2003;21:2460\u20135.","journal-title":"J Clin Oncol"},{"key":"2455_CR32","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med"},{"key":"2455_CR33","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"issue":"4","key":"2455_CR34","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","volume":"17","author":"WD Stein","year":"2011","unstructured":"Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res. 2011;17(4):907\u201317.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2455_CR35","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.2008.21.0807","volume":"27","author":"L Claret","year":"2009","unstructured":"Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009;27(25):4103\u20138.","journal-title":"J Clin Oncol"},{"key":"2455_CR36","unstructured":"Claret L, Bruno R. Wang B, Marchand M, Li C, Girish S, et al. PAGE 24 (2015) Abstr 3391 www.page-meeting.org\/?abstract=3391"},{"key":"2455_CR37","unstructured":"Claret L, Bruno R. PAGE 23 (2014) Abstr 3109 www.page-meeting.org\/?abstract=3109"},{"issue":"2","key":"2455_CR38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/clpt.2014.112","volume":"96","author":"L Claret","year":"2014","unstructured":"Claret L, Bruno R. Assessment of tumor growth inhibition metrics to predict overall survival. Clin Pharmacol Ther. 2014;96(2):135\u20137.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2455-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T22:36:32Z","timestamp":1600900592000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2455-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,13]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2455"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2455-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,13]]},"article-number":"473"}}